Food and Drug Administration (FDA) approval of Cotellic for the treatment of people with BRAF V600E or V600K mutation-positive unresectable
or metastatic melanoma in combination with Zelboraf.
These studies showed that Tafinlar + Mekinist demonstrated statistically significant progression-free survival (PFS) and overall survival (OS) compared with dabrafenib or vemurafenib, in patients with BRAF V600E/K mutation-positive unresectable
or metastatic melanoma[sup.
The resection rate was 32% in the technically unresectable
group and 40% in the >5 liver metastases group.
Currently, there are no approved maintenance therapies for patients responding to first-line treatment for unresectable
stage III NSCLC.
The FDA okayed the combination of bevacizumab, a recombinant monoclonal antibody that inhibits angiogenesis, and carboplatin and paclitaxel as initial systemic treatment of unresectable
, locally advanced, recurrent or metastatic nonsquamous non-small cell lung cancer.
Two cases remained unresectable
despite chemotherapy and radiation.
Onik, however, points out that withoutcryosurgery, the four unresectable
patients now in remission would have died.
START was a randomized, multicenter, double-blind, placebo-controlled trial that assessed the efficacy, safety and tolerability of L-BLP25 in more than 1,500 patients with unresectable
stage III NSCLC who had achieved response or stable disease after chemoradiotherapy.
Previously, Morphotek conducted a global, single-arm, open-label, Phase 2 study testing whether amatuximab plus standard of care could improve progression-free survival in patients with newly diagnosed, unresectable
, epithelioid or biphasic, malignant pleural mesothelioma.
Food and Drug Administration (FDA) has approved YONDELISA (trabectedin) for the treatment of patients with unresectable
(unable to be removed with surgery) or metastatic liposarcoma (LPS) or leiomyosarcoma (LMS) who received a prior anthracycline-containing regimen.
Merck Serono, the biopharmaceutical division of Merck, today announced the initiation of the international Phase III START2 study, which is designed to assess the efficacy and safety of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) in patients with unresectable
, locally advanced Stage III non-small cell lung cancer (NSCLC).
It is therefore important to develop strategies for reducing the chances of relapse after resection and for further increasing the chances of resection of initially unresectable